Magnetic Resonance Imaging (MRI) Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Magnetic Resonance Imaging (MRI) Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Magnetic Resonance Imaging (MRI) Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Magnetic Resonance Imaging (MRI) Contrast Agents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Magnetic Resonance Imaging (MRI) utilizes radiofrequency and a strong magnetic field to generate clear and detailed images of internal organs and tissues. MRI is generally preferred for the diagnosis of brain and other neurological disorders.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Magnetic Resonance Imaging (MRI) Contrast Agents under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Magnetic Resonance Imaging (MRI) Contrast Agents and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Magnetic Resonance Imaging (MRI) Contrast Agents under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Magnetic Resonance Imaging (MRI) Contrast Agents Overview
3 Products under Development
3.1 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
3.2 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Segment
3.3 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Territory
3.4 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Regulatory Path
3.5 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Estimated Approval Date
ADx Nanoparticle - A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients with Brain Amyloid Deposits as Demonstrated by Amyloid PET
Antaros Medical AB Pipeline Products & Ongoing Clinical Trials Overview
Gadoxetate DCE-MR Imaging Agent - Liver Toxicity - Product Status
GE HealthCare Technologies Inc - Ongoing Clinical Trials Overview
Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent - A Phase I Study to Assess the Safety Profile of Injectable Manganese Contrast Agent
Georgia State University Pipeline Products & Ongoing Clinical Trials Overview
Protein Contrast Agent - Product Status
Protein Contrast Agent - Product Description
Hana Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
HNP-2006 - Product Status
HNP-2006 - Product Description
Harvard University Pipeline Products & Ongoing Clinical Trials Overview
Hyperpolarized MRI Contrast Agent - Product Status
MRI Contrast Agent - Prostate Cancer (MT218) - An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients
Nanosion Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Polymeric Gd Agent - Product Status
Polymeric Gd Agent - Product Description
National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
Dual-Mode Contrast Agent - Product Status
Dual-Mode Contrast Agent - Product Description
Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
Gd(III) Contrast Agent - Product Status
Gd(III) Contrast Agent - Product Description
Peptide Amphiphile-Conjugated MRI Contrast Agent - Product Status